Ben Brewer’s WSJ column laments “pay for performance” measures that don’t matter. An interesting tidbit:
. . . insurance companies have us switching prescriptions for patient with high cholesterol to generic drugs from brand-name statin drugs like Lipitor and Crestor. The expectation is that the outcome will be similar. Time will tell. I can tell from my own practice data that good cholesterol, or HDL, levels have been falling since late 2006. I think this drop off in good cholesterol may be due to the generic drugs that insurers prefer.
